<DOC>
	<DOCNO>NCT01765127</DOCNO>
	<brief_summary>This post-marketing Modified Prescription-Event Monitoring ( M-PEM ) safety study asenapine ( SYCRESTÂ® ) carry Drug Safety Research Unit ( DSRU ) part Risk Management Plan require Committee Medicinal Products Human Use ( CHMP ) investigate safety profile asenapine clinical practice . The aim study proactively capture safety drug utilisation data post-marketing phase license approval asenapine prescribe patient general practitioner ( GPs ) England . This data obtain completion questionnaire GPs .</brief_summary>
	<brief_title>An Observational Modified Prescription-event Monitoring Study Asenapine ( Sycrest )</brief_title>
	<detailed_description />
	<mesh_term>Asenapine</mesh_term>
	<criteria>Patients prescribe asenapine indication NHS GPs England . Patients study questionnaire contain useful information return , include study cohort regardless dose frequency administration asenapine , irrespective whether medicine concurrently administer . patient longer register practice patient information provide study questionnaire patient information provide study questionnaire relate another antipsychotic drug patient index date improbable date ( i.e . market launch date ) patient GP report patient take never prescribe asenapine</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>